These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27055389)

  • 1. Re-recognizing serological change patterns and antiviral therapy opportunity of patients with acute hepatitis B through highly sensitive detection technology.
    Ma H; Gao M; Li J; Zhou L; Guo J; Liu J; Han X; Zhai L; Wu T
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):584-589. PubMed ID: 27055389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.
    Ito K; Yotsuyanagi H; Yatsuhashi H; Karino Y; Takikawa Y; Saito T; Arase Y; Imazeki F; Kurosaki M; Umemura T; Ichida T; Toyoda H; Yoneda M; Mita E; Yamamoto K; Michitaka K; Maeshiro T; Tanuma J; Tanaka Y; Sugiyama M; Murata K; Masaki N; Mizokami M;
    Hepatology; 2014 Jan; 59(1):89-97. PubMed ID: 23897861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
    Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
    Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment.
    Ozaras R; Tabak F; Tahan V; Ozturk R; Akin H; Mert A; Senturk H
    Dig Dis Sci; 2008 Nov; 53(11):2995-8. PubMed ID: 18409002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.
    Martin LA; Stramer SL; Kuhns MC; Schlauder GG
    Transfusion; 2012 Oct; 52(10):2201-8. PubMed ID: 22321072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of polymerase chain reaction--based detection of viral genomes in patients with serologic markers of hepatitis B or C virus infection.
    Pfeffel F; Oesterreicher C; Penner E; Ferenci P; Sillaber C; Fiedler R; Müller C
    Wien Klin Wochenschr; 1997 Jan; 109(1):20-4. PubMed ID: 9037744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of clinical characteristics and S gene mutation of hepatitis B virus (HBV) in patients with hepatitis B surface antigen RIA negative and HBV DNA positive].
    Sohn YH; Oh HB; Ko SY; Lim YS; Kwon OJ
    Korean J Lab Med; 2009 Jun; 29(3):224-30. PubMed ID: 19571620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy.
    Hsu CW; Yeh CT
    Hepatology; 2011 Jul; 54(1):101-8. PubMed ID: 21503942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.